Develops protein-degrading drug candidates for people with cancer and neurodegenerative diseases.
10-K for FY2025, filed Feb 24, 2026
Pharmaceutical partners pay Arvinas under research and licensing agreements, which can include upfront fees and research payments; revenue from the combined work is earned over the agreement period. Agreements may also bring milestone payments and royalties when customer product sales occur.
10-K for FY2025, filed Feb 24, 2026The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The Company’s revenue is primarily generated through…View ↗
Revenue is recognized ratably over the Company’s expected performance period under each respective arrangement. Management makes its best…View ↗
The Company’s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target.…View ↗
$262.6M
10-K for FY2025, filed Feb 24, 2026
$262.6M ↗
Arvinas works with pharmaceutical partners such as Pfizer and Genentech through research and licensing collaborations.
10-K for FY2025, filed Feb 24, 2026
No. It lost $80.8M in FY2025.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$53.9MView ↗
8-K, filed Aug 4, 2026
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully…View ↗
8-K, filed Jun 16, 2026
On June 11, 2026, the Company, Pfizer and Rigel received notice that early termination of the waiting period under the Hart-Scott-Rodino…View ↗
Growing. Revenue grew 4.9x in 4 years, from $53.6M in FY2021 to $262.6M in FY2025, about 49% a year.
Broader focus on neurology
The older report centered its clinical drug candidates on breast and prostate cancers; the latest report also describes candidates for neurodegenerative diseases such as Parkinson’s disease.
10-K for FY2022, filed Feb 23, 2023We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening…View ↗
Competes with Accutar Biotechnology, C4 Therapeutics, Cullgen, Foghorn Therapeutics, Kymera Therapeutics, Nurix Therapeutics, Proteovant Therapeutics, AbbVie, Amgen, Astellas Pharma, AstraZeneca, BeOne Medicines, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Genentech, Novartis, Pfizer, Sanofi, and IONIS Pharmaceuticals
10-K for FY2025, filed Feb 24, 2026Our platform and product focus is the discovery and development of protein degradation therapies using our small molecule PROTAC targeted…View ↗
Loading...